Sulfonylaminocarboxylic acids

Details Sulfonylaminocarboxylic acids Sulfonylaminocarboxylic acids

2007-01-09

2007-01-09

Rao, Deepak (Department: 1624)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Having -c-, wherein x is chalcogen, bonded directly to...

C514S378000, C546S280400, C548S247000

Reexamination Certificate

active

10170870

ABSTRACT:
Compounds of formula (I)are suitable for the production of pharmaceuticals for the prophylaxis and therapy of disorders in the course of which an increased activity of matrix-degrading metalloproteinases is involved.

REFERENCES:
patent: 5756545 (1998-05-01), O'Brien et al.
patent: 6150394 (2000-11-01), Watanabe et al.
patent: 6159995 (2000-12-01), Thorwart et al.
patent: 6207698 (2001-03-01), Wantanabe et al.
patent: 6235768 (2001-05-01), Wantanabe et al.
patent: 0 305 947 (1989-03-01), None
patent: 0 468 231 (1992-01-01), None
patent: 0 606 046 (1994-07-01), None
patent: 0 757 037 (1997-02-01), None
patent: 2263109 (1993-07-01), None
patent: WO 95/35276 (1995-12-01), None
patent: WO 96/00214 (1996-01-01), None
patent: WO 96/27583 (1996-09-01), None
patent: WO 96/33172 (1996-10-01), None
patent: WO 97/19068 (1997-05-01), None
patent: WO 97/27174 (1997-07-01), None
Lechan et al., Endocrinology, Editorial: Hypotharlmic Melanocortin Signalling in Cachexia, 142(8):3288-3291, 2001.
Avgeropoulos et al., New Treatment Strategies for Malignant Gliomas, The Oncologist, 4:209-224, 1999.
Simone, Oncology: Introduction, Cecil Textbook of Medicine, 20thEdition, vol. 1, pp. 1004-1010, 1996.
Catterall et al., Drugs in development: bisphosphonates and metalloproteinase inhibitors, Arthritis Research and Therapy, vol. 5, No. 1, pp. 12-24, 2003.
Visse et al., Matrix Metalloproteinases and Tissue Inhibitors of Metalloproteinases, Circulation Research, 92:827-839, 2003.
Sonis, The Pathology of Mucositis, Nat Rev Cancer, 4(4):277-284, 2004.
Armstrong et al., PubMed Abstract (J Am Podiatr Med Assoc. 92(1):12-8), Jan. 2002.
Morris et al., Sequential Steps in Hematogenous Metastasis of Cancer Cells Studied by in vivo Videomicroscopy, Invasion Metastasis, 17:281-296, 1997.
Chambers et al., Changing views of the role of Matrix Metalloproteinases in Metastasis, Journal of the National Cancer Institute, vol. 89, No. 17, Sep. 1997.
Rasmussen et al., Matrix Metalloproteinase Inhibition as a novel anticancer strategy, Pharmacol. Ther., vol. 75, No. 1, pp. 69-75, 1997.
Bassin, Jatinder P. et al., “Chlorosulfonation of Some Polynuclear Heterocyclic Compounds,”Phosporus, Sulfur, and Silicon, vol. 72, pp. 157-170 (1992).
Fosang, Amanda J. et al., “Aggrecan Is Degraded by Matrix Metalloproteinases in Human Arthritis: Evidence that Matrix Metalloproteinase and Aggecanase Activities Can Be Independent,”J. Clin. Invest.,, vol. 98, No. 10, pp. 2292-2299 (Nov. 1996).
Roemmele, Renee C. and Rapoport, Henry, “Removal of N-Arylsulfonyl Groups from Hydroxy α-Amino Acids,”J. Org. Chem., vol. 53, pp. 2367-2371 (1988).
Suter, C. M., “Studies in the Diphenyl Ether Series. II. Preparation and Structure of Some Sulfonic Acids and Related Derivatives,”J. Am. Chem. Soc., vol. 53, pp. 1112-1116 (1931).
Want, Su-Sun, “ρ-Alkoxybenzyl Alcohol Resin and ρ-Alkoxybenzyloxycarbonylhydrazide Resin for Solid Phase Synthesis of Protected Peptide Fragments,”J. Am. Chem. Soc., vol. 95, No. 4, pp. 1328-1333 (Feb. 21, 1973).
Ye, Qi-Zhuang et al., “Purification and Characterization of the Human Stromelysin Catalytic Domain Expressed inEscherichia coli,”J. Biochemistry, vol. 31, pp. 11231-11235 (1992).

Affiliated with

Also associated with

Rating

Sulfonylaminocarboxylic acids does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Sulfonylaminocarboxylic acids, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Sulfonylaminocarboxylic acids will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3792016